A study to determine the optimal dose of Tarceva [erlotinib], in combination with irinotecan and Xeloda [capacitabine], as second line therapy in patients with metastatic colorectal cancer.
Phase of Trial: Phase II
Latest Information Update: 23 Feb 2010
At a glance
- Drugs Capecitabine; Erlotinib; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Roche
- 10 Jan 2008 Status change
- 29 May 2007 New trial record.